---
layout: default
title: Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery
---

# Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2509.14788" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2509.14788v1</a>
  <a href="https://arxiv.org/pdf/2509.14788.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2509.14788v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2509.14788v1', 'Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Jing Lan, Hexiao Ding, Hongzhao Chen, Yufeng Jiang, Nga-Chun Ng, Gwing Kei Yip, Gerald W. Y. Cheng, Yunlin Mao, Jing Cai, Liang-ting Lin, Jung Sun Yoo

**åˆ†ç±»**: cs.LG, cs.AI, q-bio.BM

**å‘å¸ƒæ—¥æœŸ**: 2025-09-18

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºç»“æ„æ„ŸçŸ¥å¯¹æ¯”å­¦ä¹ æ¡†æ¶ï¼Œç»“åˆç²¾ç»†ç»“åˆè¡¨å¾ï¼Œæå‡è¯ç‰©å‘ç°ä¸­DTIé¢„æµ‹æ€§èƒ½ã€‚**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±äºŒï¼šRLç®—æ³•ä¸æ¶æ„ (RL & Architecture)**

**å…³é”®è¯**: `è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨é¢„æµ‹` `å¯¹æ¯”å­¦ä¹ ` `ç»“æ„æ„ŸçŸ¥` `è¯ç‰©å‘ç°` `è™šæ‹Ÿç­›é€‰`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç°æœ‰åŸºäºåºåˆ—çš„DTIé¢„æµ‹æ–¹æ³•ç¼ºä¹ç»“æ„ä¿¡æ¯ï¼Œé™åˆ¶äº†é¢„æµ‹å‡†ç¡®æ€§ï¼Œå°¤å…¶æ˜¯åœ¨å¤æ‚ç›¸äº’ä½œç”¨åœºæ™¯ä¸‹ã€‚
2. è¯¥è®ºæ–‡æå‡ºä¸€ç§ç»“æ„æ„ŸçŸ¥çš„å¯¹æ¯”å­¦ä¹ æ¡†æ¶ï¼Œé€šè¿‡æ•´åˆç»“æ„å…ˆéªŒçŸ¥è¯†å¢å¼ºè›‹ç™½è´¨è¡¨å¾ï¼Œæå‡DTIé¢„æµ‹æ€§èƒ½ã€‚
3. å®éªŒè¡¨æ˜ï¼Œè¯¥æ¨¡å‹åœ¨å¤šä¸ªæ•°æ®é›†ä¸Šè¶…è¶Šç°æœ‰æ–¹æ³•ï¼Œå¹¶åœ¨è™šæ‹Ÿç­›é€‰ä»»åŠ¡ä¸­å–å¾—æ˜¾è‘—æå‡ï¼ŒéªŒè¯äº†æ¡†æ¶çš„æœ‰æ•ˆæ€§ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨ï¼ˆDTIï¼‰çš„å‡†ç¡®è¯†åˆ«ä»ç„¶æ˜¯è®¡ç®—è¯ç†å­¦ä¸­çš„æ ¸å¿ƒæŒ‘æˆ˜ï¼Œå…¶ä¸­åŸºäºåºåˆ—çš„æ–¹æ³•æä¾›äº†å¯æ‰©å±•æ€§ã€‚æœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§åŸºäºåºåˆ—çš„è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨æ¡†æ¶ï¼Œè¯¥æ¡†æ¶å°†ç»“æ„å…ˆéªŒçŸ¥è¯†æ•´åˆåˆ°è›‹ç™½è´¨è¡¨å¾ä¸­ï¼ŒåŒæ—¶ä¿æŒé«˜é€šé‡ç­›é€‰èƒ½åŠ›ã€‚åœ¨å¤šä¸ªåŸºå‡†æ•°æ®é›†ä¸Šè¯„ä¼°ï¼Œè¯¥æ¨¡å‹åœ¨Humanå’ŒBioSNAPæ•°æ®é›†ä¸Šå–å¾—äº†æœ€å…ˆè¿›çš„æ€§èƒ½ï¼Œå¹¶åœ¨BindingDBä¸Šä¿æŒäº†ç«äº‰åŠ›ã€‚åœ¨è™šæ‹Ÿç­›é€‰ä»»åŠ¡ä¸­ï¼Œå®ƒè¶…è¶Šäº†LIT-PCBAä¸Šçš„ç°æœ‰æ–¹æ³•ï¼Œåœ¨AUROCå’ŒBEDROCæ–¹é¢äº§ç”Ÿäº†æ˜¾è‘—çš„æå‡ã€‚æ¶ˆèç ”ç©¶è¯å®äº†å­¦ä¹ åˆ°çš„èšåˆã€åŒçº¿æ€§æ³¨æ„åŠ›å’Œå¯¹æ¯”å¯¹é½åœ¨å¢å¼ºé¢„æµ‹é²æ£’æ€§æ–¹é¢çš„å…³é”®ä½œç”¨ã€‚åµŒå…¥å¯è§†åŒ–æ˜¾ç¤ºï¼Œä¸å·²çŸ¥çš„ç»“åˆå£è¢‹å…·æœ‰æ›´å¥½çš„ç©ºé—´å¯¹åº”æ€§ï¼Œå¹¶çªå‡ºäº†é…ä½“-æ®‹åŸºæ¥è§¦çš„å¯è§£é‡Šæ³¨æ„åŠ›æ¨¡å¼ã€‚è¿™äº›ç»“æœéªŒè¯äº†è¯¥æ¡†æ¶åœ¨å¯æ‰©å±•å’Œç»“æ„æ„ŸçŸ¥çš„DTIé¢„æµ‹ä¸­çš„æ•ˆç”¨ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³è¯ç‰©å‘ç°ä¸­è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨ï¼ˆDTIï¼‰é¢„æµ‹çš„å‡†ç¡®æ€§é—®é¢˜ã€‚ç°æœ‰åŸºäºåºåˆ—çš„æ–¹æ³•è™½ç„¶å…·æœ‰å¯æ‰©å±•æ€§ï¼Œä½†å¿½ç•¥äº†è›‹ç™½è´¨çš„ç»“æ„ä¿¡æ¯ï¼Œå¯¼è‡´é¢„æµ‹ç²¾åº¦å—é™ï¼Œå°¤å…¶æ˜¯åœ¨å¤„ç†å¤æ‚çš„è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨æ—¶ã€‚å› æ­¤ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°å°†ç»“æ„ä¿¡æ¯èå…¥åˆ°åŸºäºåºåˆ—çš„DTIé¢„æµ‹æ¨¡å‹ä¸­ï¼Œæ˜¯æœ¬æ–‡è¦è§£å†³çš„æ ¸å¿ƒé—®é¢˜ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒæ€è·¯æ˜¯å°†è›‹ç™½è´¨çš„ç»“æ„å…ˆéªŒçŸ¥è¯†èå…¥åˆ°è›‹ç™½è´¨çš„åºåˆ—è¡¨å¾ä¸­ï¼Œä»è€Œæé«˜DTIé¢„æµ‹çš„å‡†ç¡®æ€§ã€‚å…·ä½“æ¥è¯´ï¼Œé€šè¿‡å¯¹æ¯”å­¦ä¹ çš„æ–¹å¼ï¼Œå°†è›‹ç™½è´¨åºåˆ—ç¼–ç ä¸ç»“æ„ä¿¡æ¯å¯¹é½ï¼Œä½¿å¾—æ¨¡å‹èƒ½å¤Ÿå­¦ä¹ åˆ°æ›´å…·ç»“æ„æ„ŸçŸ¥çš„è›‹ç™½è´¨è¡¨å¾ã€‚è¿™ç§æ–¹æ³•æ—¢ä¿ç•™äº†åºåˆ—æ–¹æ³•çš„å¯æ‰©å±•æ€§ï¼Œåˆåˆ©ç”¨äº†ç»“æ„ä¿¡æ¯çš„ä¼˜åŠ¿ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šè¯¥æ¡†æ¶ä¸»è¦åŒ…å«ä»¥ä¸‹å‡ ä¸ªæ¨¡å—ï¼š1) è›‹ç™½è´¨åºåˆ—ç¼–ç æ¨¡å—ï¼Œç”¨äºå°†è›‹ç™½è´¨åºåˆ—è½¬åŒ–ä¸ºå‘é‡è¡¨ç¤ºï¼›2) ç»“æ„ä¿¡æ¯ç¼–ç æ¨¡å—ï¼Œç”¨äºæå–è›‹ç™½è´¨çš„ç»“æ„ç‰¹å¾ï¼›3) å¯¹æ¯”å­¦ä¹ æ¨¡å—ï¼Œé€šè¿‡å¯¹æ¯”å­¦ä¹ æŸå¤±å‡½æ•°ï¼Œå°†åºåˆ—ç¼–ç å’Œç»“æ„ä¿¡æ¯å¯¹é½ï¼›4) DTIé¢„æµ‹æ¨¡å—ï¼ŒåŸºäºå­¦ä¹ åˆ°çš„è›‹ç™½è´¨è¡¨å¾ï¼Œé¢„æµ‹è¯ç‰©-é¶æ ‡ä¹‹é—´çš„ç›¸äº’ä½œç”¨ã€‚æ•´ä½“æµç¨‹æ˜¯ï¼šé¦–å…ˆå¯¹è›‹ç™½è´¨åºåˆ—å’Œç»“æ„ä¿¡æ¯è¿›è¡Œç¼–ç ï¼Œç„¶åé€šè¿‡å¯¹æ¯”å­¦ä¹ è¿›è¡Œå¯¹é½ï¼Œæœ€ååˆ©ç”¨å¯¹é½åçš„è¡¨å¾è¿›è¡ŒDTIé¢„æµ‹ã€‚

**å…³é”®åˆ›æ–°**ï¼šè¯¥è®ºæ–‡çš„å…³é”®åˆ›æ–°åœ¨äºå°†ç»“æ„å…ˆéªŒçŸ¥è¯†ä»¥å¯¹æ¯”å­¦ä¹ çš„æ–¹å¼èå…¥åˆ°åŸºäºåºåˆ—çš„DTIé¢„æµ‹æ¨¡å‹ä¸­ã€‚ä¸ä¼ ç»Ÿçš„ç›´æ¥å°†ç»“æ„ä¿¡æ¯ä½œä¸ºè¾“å…¥ç‰¹å¾çš„æ–¹æ³•ä¸åŒï¼Œè¯¥æ–¹æ³•é€šè¿‡å¯¹æ¯”å­¦ä¹ ï¼Œä½¿å¾—æ¨¡å‹èƒ½å¤Ÿè‡ªåŠ¨å­¦ä¹ åˆ°åºåˆ—å’Œç»“æ„ä¹‹é—´çš„å…³è”ï¼Œä»è€Œæ›´å¥½åœ°åˆ©ç”¨ç»“æ„ä¿¡æ¯ã€‚æ­¤å¤–ï¼Œè®ºæ–‡è¿˜æå‡ºäº†ç²¾ç»†çš„ç»“åˆè¡¨å¾æ–¹æ³•ï¼Œè¿›ä¸€æ­¥æå‡äº†æ¨¡å‹çš„é¢„æµ‹æ€§èƒ½ã€‚

**å…³é”®è®¾è®¡**ï¼šåœ¨å¯¹æ¯”å­¦ä¹ æ¨¡å—ä¸­ï¼Œä½¿ç”¨äº†InfoNCEæŸå¤±å‡½æ•°ï¼Œç”¨äºæœ€å¤§åŒ–æ­£æ ·æœ¬ä¹‹é—´çš„ç›¸ä¼¼åº¦ï¼Œæœ€å°åŒ–è´Ÿæ ·æœ¬ä¹‹é—´çš„ç›¸ä¼¼åº¦ã€‚åœ¨è›‹ç™½è´¨åºåˆ—ç¼–ç æ¨¡å—ä¸­ï¼Œä½¿ç”¨äº†Transformeræ¨¡å‹ï¼Œç”¨äºæ•æ‰åºåˆ—ä¸­çš„é•¿ç¨‹ä¾èµ–å…³ç³»ã€‚åœ¨ç»“æ„ä¿¡æ¯ç¼–ç æ¨¡å—ä¸­ï¼Œä½¿ç”¨äº†å›¾ç¥ç»ç½‘ç»œï¼Œç”¨äºæå–è›‹ç™½è´¨çš„ç»“æ„ç‰¹å¾ã€‚æ­¤å¤–ï¼Œè®ºæ–‡è¿˜è®¾è®¡äº†åŒçº¿æ€§æ³¨æ„åŠ›æœºåˆ¶ï¼Œç”¨äºæ•æ‰è¯ç‰©å’Œé¶æ ‡ä¹‹é—´çš„ç›¸äº’ä½œç”¨ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

è¯¥æ¨¡å‹åœ¨Humanå’ŒBioSNAPæ•°æ®é›†ä¸Šå–å¾—äº†state-of-the-artçš„æ€§èƒ½ï¼Œå¹¶åœ¨BindingDBæ•°æ®é›†ä¸Šä¿æŒäº†ç«äº‰åŠ›ã€‚åœ¨LIT-PCBAè™šæ‹Ÿç­›é€‰ä»»åŠ¡ä¸­ï¼ŒAUROCå’ŒBEDROCæŒ‡æ ‡å‡è¶…è¶Šäº†ç°æœ‰æ–¹æ³•ï¼Œå–å¾—äº†æ˜¾è‘—æå‡ã€‚æ¶ˆèå®éªŒéªŒè¯äº†å­¦ä¹ åˆ°çš„èšåˆã€åŒçº¿æ€§æ³¨æ„åŠ›å’Œå¯¹æ¯”å¯¹é½åœ¨æå‡é¢„æµ‹é²æ£’æ€§æ–¹é¢çš„å…³é”®ä½œç”¨ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶æˆæœå¯åº”ç”¨äºè¯ç‰©å‘ç°çš„æ—©æœŸé˜¶æ®µï¼Œç”¨äºé«˜é€šé‡ç­›é€‰æ½œåœ¨çš„è¯ç‰©-é¶æ ‡ç›¸äº’ä½œç”¨ã€‚é€šè¿‡æé«˜DTIé¢„æµ‹çš„å‡†ç¡®æ€§ï¼Œå¯ä»¥å‡å°‘æ¹¿å®éªŒçš„æ¬¡æ•°ï¼Œé™ä½è¯ç‰©ç ”å‘çš„æˆæœ¬å’Œæ—¶é—´ã€‚æ­¤å¤–ï¼Œè¯¥æ–¹æ³•è¿˜å¯ä»¥ç”¨äºé¢„æµ‹è¯ç‰©çš„å‰¯ä½œç”¨å’Œæ¯’æ€§ï¼Œä»è€Œæé«˜è¯ç‰©çš„å®‰å…¨æ€§ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Accurate identification of drug-target interactions (DTI) remains a central challenge in computational pharmacology, where sequence-based methods offer scalability. This work introduces a sequence-based drug-target interaction framework that integrates structural priors into protein representations while maintaining high-throughput screening capability. Evaluated across multiple benchmarks, the model achieves state-of-the-art performance on Human and BioSNAP datasets and remains competitive on BindingDB. In virtual screening tasks, it surpasses prior methods on LIT-PCBA, yielding substantial gains in AUROC and BEDROC. Ablation studies confirm the critical role of learned aggregation, bilinear attention, and contrastive alignment in enhancing predictive robustness. Embedding visualizations reveal improved spatial correspondence with known binding pockets and highlight interpretable attention patterns over ligand-residue contacts. These results validate the framework's utility for scalable and structure-aware DTI prediction.

